跳转至内容
Merck
CN
所有图片(1)

主要文件

查看所有文档

B2292

Sigma-Aldrich

O6-苄基鸟嘌呤

≥98% (TLC), solid, O⁶-alkylguanine DNA alkyltransferase inhiitor

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C12H11N5O
CAS号:
19916-73-5
分子量:
241.25
MDL编号:
MFCD00269931
UNSPSC代码:
12352200
PubChem化学物质编号:
24278259
NACRES:
NA.77

产品名称

O6-苄基鸟嘌呤, ≥98% (TLC), solid

质量水平

200

方案

≥98% (TLC)

表单

solid

溶解性

methanol: 20 mg/mL

储存温度

room temp

SMILES字符串

Nc1nc(OCc2ccccc2)c3nc[nH]c3n1

InChI

1S/C12H11N5O/c13-12-16-10-9(14-7-15-10)11(17-12)18-6-8-4-2-1-3-5-8/h1-5,7H,6H2,(H3,13,14,15,16,17)

InChI key

KRWMERLEINMZFT-UHFFFAOYSA-N

基因信息

human ... MGMT(4255)

正在寻找类似产品? 访问 产品对比指南

应用

使用O6-苄基鸟嘌呤：
  • 用作胶质母细胞瘤干细胞中甲基鸟嘌呤甲基转移酶(MGMT)抑制剂
  • 在N-乙基-N-亚硝基脲(ENU)疗法之前用作胚胎干细胞中的O6-烷基鸟嘌呤-烷基转移酶(AGT)的酶抑制剂
  • 在HL-60人早幼粒白血病生长抑制试验中AGT的抑制剂

生化/生理作用

O(6)-苄基鸟嘌呤是一种抗肿瘤剂，它通过与DNA修复酶O(6)-烷基鸟嘌呤DNA烷基转移酶（AGT）结合，抑制AGT介导的DNA修复。它被广泛用于各种DNA修复机制研究，并且可加强其他破坏DNA的化疗药物的作用。
O6-苄基鸟嘌呤(O6BG)可通过苄基转移阻断活性部位来抑制甲基鸟嘌呤甲基转移酶(MGMT)。使用O6BG与双氯乙基亚硝基脲(BCNU)或卡莫司汀治疗包括淋巴瘤、黑色素瘤和肉瘤等实体肿瘤是有效的。

象形图

Exclamation mark
GHS07

警示用语：

Warning

危险声明

H315,H319,H335

危险分类

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

靶器官

Respiratory system

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

dust mask type N95 (US), Eyeshields, Gloves

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000354417
0000351536
0000354417
0000351536
0000252699

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Mako Kamiya et al.
Analytical chemistry, 82(15), 6472-6479 (2010-07-02)
We introduce here a new class of BODIPY-based Ca2+ indicators which can be derivatized with biological ligands that permit the localization of the indicators in living cells. The underivatized BODIPY-based Ca2+ indicator (BOCA-1) shows a 250-fold increase in fluorescence intensity
Lynn Martin et al.
Radiation research, 172(4), 405-413 (2009-09-24)
Low-dose hyper-radiosensitivity (HRS) is the phenomenon whereby cells exposed to radiation doses of less than approximately 0.5 Gy exhibit increased cell killing relative to that predicted from back-extrapolating high-dose survival data using a linear-quadratic model. While the exact mechanism remains
Brian C Beard et al.
The Journal of clinical investigation, 120(7), 2345-2354 (2010-06-17)
HSC transplantation using genetically modified autologous cells is a promising therapeutic strategy for various genetic diseases, cancer, and HIV. However, for many of these conditions, the current efficiency of gene transfer to HSCs is not sufficient for clinical use. The
A Phase III study of radiation therapy (RT) and O 6-benzylguanine+ BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001
Blumenthal DT, et al.
International Journal of Clinical Oncology, 20(4), 650-658 (2015)
Andre Larochelle et al.
The Journal of clinical investigation, 119(7), 1952-1963 (2009-06-11)
Major limitations to gene therapy using HSCs are low gene transfer efficiency and the inability of most therapeutic genes to confer a selective advantage on the gene-corrected cells. One approach to enrich for gene-modified cells in vivo is to include
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门